Schwetz B, Gaylor D
Food and Drug Administration/National Center for Toxicological Research, Jefferson, Arkansas 72079-9502, USA.
Mol Carcinog. 1997 Nov;20(3):275-9. doi: 10.1002/(sici)1098-2744(199711)20:3<275::aid-mc3>3.0.co;2-k.
Carcinogenicity testing today normally includes conducting 2-yr studies of rats and mice of both sexes and following widely accepted procedures for husbandry, selection of dose levels, pathology and toxicity observations, and statistical interpretation of tumor data. These studies are usually preceded by tests for genetic toxicity and subchronic toxicity studies to select dose levels for the 2-yr studies. While these data are used for quantitative risk assessment, the mechanistic basis for effects is usually unknown, and such series of studies are very expensive and require five or more years to conduct. Alternate approaches are being developed that would provide more mechanistic information and perhaps would permit decisions to be made about carcinogenic potential without the need to conduct 2-yr studies of rats and mice of both sexes. Decisions could be based on a profile of data rather than the result of one test. Regulatory acceptance of new approaches for carcinogenicity testing is critical to future progress in the field of carcinogenesis.
如今的致癌性测试通常包括对雌雄大鼠和小鼠进行为期两年的研究,并遵循关于饲养、剂量水平选择、病理学和毒性观察以及肿瘤数据统计解释的广泛接受的程序。这些研究通常之前会进行遗传毒性测试和亚慢性毒性研究,以选择两年研究的剂量水平。虽然这些数据用于定量风险评估,但效应的机制基础通常未知,而且这样一系列的研究非常昂贵,需要五年或更长时间来进行。正在开发替代方法,这些方法将提供更多的机制信息,也许可以在无需对雌雄大鼠和小鼠进行两年研究的情况下就致癌潜力做出决策。决策可以基于一系列数据而不是一次测试的结果。监管机构接受新的致癌性测试方法对于致癌作用领域的未来进展至关重要。